- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03271853
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
FirstSense Medical, LLC is a medical device company which has developed a breast cancer screening device, the Sentinel BreastScan II [SBS II]. This radiation free device is being developed to produce data which will be analyzed by Therma-Scan Reference Laboratory. Dr. Hoekstra, CEO of Therma-Scan, is the author of a published paper based on breast thermal data with a reported 95% sensitivity and 91% specificity. The SBS II examination will take approximately 7 minutes.
This study is designed to evaluate the Sentinel BreastScan II as well as the analysis of data by Therma-Scan. SBS II thermal breast data is an adjunctive aid to standard breast imaging. Currently, mammography is one of the standards of care in screening for visible signs of breast cancer. Breast thermology is the analysis of the heat signature data from an examined breast. All study costs will be incurred by the sponsor. Study subjects will incur no cost to participate. All scientific data revealed in this protocol will be used for the specific objectives of the study. The SBS II is a non-significant risk device. There is no contact with the subject during the entire procedure.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Ohio
-
Toledo, Ohio, United States, 43614
- Eleanor N. Dana Cancer Center, University of Toledo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or Female, over the age of 18 years of age.
- Asymptomatic women or women who are being screened for breast abnormality.
- Women scheduled for a mammogram or women who have had a mammogram and are given 3 days to wait in between their mammogram and scheduled biopsy and FS/TS system.
- Not pregnant or breast feeding.
- Signed Informed consent.
Exclusion Criteria:
- Subject does not meet inclusion criteria, noted above.
- Use of 100 mg or more of niacin by tablet or niacin patch within the last 24 hours.
- Use of nitroglycerin within the last 24 hours.
- Subject experienced a fever of 102°F or higher within thirty-six (36) hours of the study.
- Subject must not have had a mammogram, breast ultrasound, or breast exam within the last 72 hours prior to the SBS II.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
SBS II
|
The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature.
The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast.
SBS II captures this data digitally for subsequent analysis by Therma-Scan.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure protocol accuracy
Time Frame: Through study completion, an average of 4 years.
|
To measure the sensitivity and specificity of thermographic analysis based on the Marseilles analytic protocol [ Th 1 thru 5 ] to biopsy results predicated on standard breast imaging criteria [ BIRADS analytical protocol, B1 thru B5 ].
The resultant BIRADS score and biopsy pathological results will be compared to thermographic analysis [ Th1 thru 5 ] for each subject.
50 subjects undergoing both thermography and standard breast imaging leading to biopsy [ BIRADS 3 thru 5 ] will then be compared by measuring the results of each, BIRADS for standard breast imaging v the Marseilles Th system used in thermographic analysis, for concordance or discordance of findings as measured on final pathological analysis.
This analysis will be performed for each subsequent 50 patient cohort undergoing standard mammographic/ultrasound breast imaging analysis.
|
Through study completion, an average of 4 years.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Haitham Elsamaloty, University of Toledo
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SBS-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasm Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Clinical Research Centre, MalaysiaMinistry of Health, Malaysia; National University of Malaysia; Institute for...Not yet recruitingBreast Neoplasm FemaleMalaysia
-
Peking University Cancer Hospital & InstituteRecruiting
-
Peking University Cancer Hospital & InstituteNot yet recruiting
-
University of Rome Tor VergataRecruiting
-
Mario Negri Institute for Pharmacological ResearchRecruiting
-
Peter MacCallum Cancer Centre, AustraliaRecruitingBreast Neoplasm FemaleAustralia
-
Tongji HospitalThe First Affiliated Hospital with Nanjing Medical University; Qilu Hospital... and other collaboratorsNot yet recruitingBreast Neoplasm Female
-
University of CopenhagenUniversity of Southern DenmarkCompleted
-
Mackay Medical CollegeTaipei Veterans General Hospital, TaiwanCompletedBreast Neoplasm Female
Clinical Trials on Sentinel BreastScan II
-
Institut Cancerologie de l'OuestCompleted
-
Duk-Woo Park, MDBoston Scientific Corporation; CardioVascular Research Foundation, KoreaRecruitingAortic Valve Disease | Transcatheter Aortic Valve Replacement | Transcatheter Aortic Valve ImplantationKorea, Republic of
-
PRo-IVBait Balev HospitalUnknownSepsis | CHF | BacteriemiaIsrael
-
CVPath Institute Inc.Boston Scientific CorporationCompleted
-
The Netherlands Cancer InstituteNot yet recruitingTesticular Germ Cell Tumor
-
National Cancer Center, KoreaRecruitingFeasibility Study of Sentinel Navigation Surgery After Non-curative Endoscopic Resection (SENORITA2)Early Gastric Cancer | Sentinel Lymph NodeKorea, Republic of
-
Diana ZachSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...CompletedSentinel Lymph Node | Vulva CancerSweden
-
Imperial College LondonSt Mary's Hospital, LondonSuspendedStroke | Silent Cerebral InfarctUnited Kingdom
-
Instituto de Investigacion Sanitaria La FeCompleted
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedBreast Neoplasm Female